RespireRx Pharmaceuticals Inc (fka RSPI)

[crazy horse 0]

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and
Potential Strategic Partners and Other Interested Parties


We intend to maintain, expand and enhance our intellectual property portfolio.

Pending the receipt of adequate finance, of which no assurance can be provided, we plan to activate or replace our
IND for CX717, and engage in research, preclinical and clinical development beyond the scope of existing grant
awards and grants applied.

And a Thank You

We would like to thank all of our shareholders, strategic vendors/collaborators, service providers, strategic partners
and all other stakeholders for their patience and for standing with us as we advance the RespireRx Group and what
we consider to be its very valuable and important assets.

And as we said in a press release/letter on February 10, 2025, we continue to believe that together, we can advance
life-changing therapies, create value for our investors and other stakeholders, and positively impact the lives
of patients worldwide.

https://respirerx.com/wp-content/uploads/2025/11/Press-Release-Letter-to-shareholders-and-stakeholder-11202025-APPROVED-for-distribution-FINAL.pdf